Press Releases

Press Releases

All Releases
Mar 08, 2016
Webcast Available Through Ophthotech Website NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Barclays Global Healthcare Conference 2016 in
Feb 24, 2016
- Conference Call and Webcast Today, February 24 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the fourth quarter and full year ended December 31, 2015 and provided an update on the Company's business and product
Feb 18, 2016
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the RBC Capital Markets Healthcare Conference
Feb 17, 2016
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its fourth quarter and year ended December 31, 2015 financial results on Wednesday, February 24, 2016 . Following the announcement, Ophthotech's management team will host a live conference call
Feb 03, 2016
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the LEERINK Partners 5th Annual Global
Jan 27, 2016
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) announced that the first patient has been dosed in a Phase 2/3 clinical study of Zimura ® (avacincaptad pegol sodium), an inhibitor of complement factor C5, in patients with geographic atrophy, an advanced form of dry
Jan 06, 2016
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced the appointment of David E. Redlick to its Board of Directors effective immediately. David Redlick recently retired as a Partner in the Corporate Practice Group at Wilmer Cutler Pickering Hale and Dorr LLP
Jan 05, 2016
Michael G. Atieh to Retire as Executive Vice President and Chief Financial and Business Officer; Transition Expected at End of First Quarter 2016 - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation ( NASDAQ : OPHT) today announced that Glenn P. Sblendorio, a leading industry veteran, has agreed
Jan 04, 2016
Webcast Available Through Ophthotech Website NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation ( NASDAQ : OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 34th Annual J.P.
Dec 02, 2015
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation ( NASDAQ : OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Oppenheimer 26th Annual Healthcare
Dec 01, 2015
- Webcast to Begin at 8:30 a.m. Eastern Time - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that the Company will host a live webcast in conjunction with its Research and Development (R&D) Investor Day on Thursday, December 3, 2015 , beginning at 8:30 a.m. ET.
Nov 12, 2015
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation ( NASDAQ : OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 2015 Stifel Healthcare Conference in New
Nov 05, 2015
- Conference Call and Webcast Today, November 5, 2015 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the third quarter ended September 30, 2015 and provided an update on the Company's business and product development
Nov 02, 2015
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its third quarter 2015 financial results on Thursday, November 5, 2015 . Following the announcement, Ophthotech's management team will host a live conference call and webcast at 8:00 a.m.
Oct 26, 2015
- Initial, Topline Data From Both Phase 3 Trials of Fovista ® in Combination with Lucentis ® Expected to be Available in 4Q 2016 - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced the completion of patient recruitment for its second Phase 3 trial of
Sep 02, 2015
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) today reported that in connection with the appointment of Henric Bjarke , Senior Vice President and Chief Commercial Officer, the Company entered into an employment arrangement with Mr.
Aug 05, 2015
Conference Call and Webcast Today, August 5, 2015 , at 8:00 a.m. ET NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the second quarter ended June 30, 2015 and provided an update on the Company's business and product development programs.
Jul 29, 2015
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its second quarter 2015 financial results on Wednesday, August 5, 2015 . Following the announcement, Ophthotech's management team will host a live conference call and webcast at 8:00 a.m.
Jul 21, 2015
Dr. David T. Shima , a Pioneer, World Leader and Expert in Ocular Angiogenesis and Vascular Cell Biology, Appointed Chief Scientific Officer - Henric Bjarke Joins as Chief Commercial Officer; Brings a Proven Track Record with Major Product Launches and Ophthalmic Domain Expertise - NEW YORK